(Q35122185)

6 August 2017

1 reference

title

'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning (English)

1 reference

6 August 2017

0 references

1

Porter DL

1 reference

6 August 2017

2

Stadtmauer EA

1 reference

6 August 2017

Lazarus HM

3

1 reference

PubMed ID

12732878

6 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

Bone Marrow Transplantation

6 August 2017

1 reference

6 August 2017

31

1 reference

6 August 2017

9

1 reference

6 August 2017

739-746

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703895

6 August 2017

0 references

cites work

Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Identical-twin bone marrow transplants for leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Donor leukocyte infusions in acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Long-term results of blood and marrow transplantation for Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Allogeneic marrow transplantation for refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Second allogeneic transplantation after failure of first autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Donor leukocyte infusions for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703895

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703895

1 reference

6 August 2017

1 reference

PubMed ID

12732878